Showing 1991-2000 of 23132 results for "".
First Cell-Based Gene Therapy for RDEB
https://reachmd.com/series/dermwire-tv/first-cell-based-gene-therapy-for-rdeb/35742/In this week's DermwireTV, the FDA approves the first cell-based gene therapy for recessive dystophic epidermolysis bullosa (RDEB); a new acne scar treatment using focal point technology is cleared in the US; and in our “Updates on Skin Cancer” feature, we hear about the advantages of 40-GEP testingAddressing Barriers to Colorectal Cancer Screening in Rural Populations
https://reachmd.com/programs/clinicians-roundtable/addressing-barriers-to-colorectal-cancer-screening-in-rural-populations/33056/Rural populations face unique challenges in accessing colorectal cancer screening, leaving many patients in these communities unscreened. However, mailed fecal immunochemical testing (FIT) may help address these barriers and improve adherence. Joining Dr. Peter Buch to discuss the benefits and limitSocial Media & Heart Health: Insights from ACC.23
https://reachmd.com/programs/acc-action-center/social-media-heart-health-insights-from-acc23/15142/Can Facebook friendships impact heart health? Find out what we learned on Day 3 of the American College of Cardiology's Scientific Session & Expo.The Use of Anticoagulants and Antiplatelet Medications in Cirrhosis
https://reachmd.com/programs/gi-insights/the-use-of-anticoagulants-and-antiplatelet-medications-in-cirrhosis/15875/What can we learn about the safety of anticoagulants and antiplatelet agents in patients with cirrhosis from a recent article? Dive in.High-Tech Cardiovascular Risk Assessment
https://reachmd.com/programs/lipid-luminations/high-tech-cardiovascular-risk-assessment/3570/The means for assessing cardiovascular risk include several new high technology developments. Dr. James Ehrlich, MD, a veteran in the development of advanced coronary risk assessment centers, educates us on the role of electron beam computed tomography (EBCT), endothelial function testing, andImplications of the ACCORD, ADVANCE and VA Diabetes Trials
https://reachmd.com/programs/diabetes-discourse/implications-of-the-accord-advance-and-va-diabetes-trials/5006/The ACCORD, ADVANCE and VA Diabetes Trials seem to indicate that there is no real benefit of intensive glycemic control on cardiovascular events in patients with type 2 diabetes. Join host Dr. Steven Edelman and his guest, executive director of the International Diabetes Center at Park Nicollet, Dr.Special Report: What Went Wrong With ACCORD?
https://reachmd.com/programs/clinicians-roundtable/special-report-what-went-wrong-with-accord/3205/What went wrong with the glucose-lowering arm of the ACCORD (Action to Control Cardiovascular Risk in Diabetes) Trials? Intensive therapy was expected to reduce cardiovascular events in Type 2 diabetics at high risk of cardiovascular disease. Instead, it appears to have led to an increase in moCurrent Surgical and Non-Surgical Techniques in Articular Cartilage Repair
https://reachmd.com/programs/clinicians-roundtable/current-surgical-and-non-surgical-techniques-in-articular-cartilage-repair/3672/When articular cartilage is damaged orthopedic intervention is required. Dr. Riley Williams, associate professor of orthopedic surgery at Weill Medical College, director of the institute for cartilage repair at the Hospital for Special Surgery, and a leading expert on cartilage repair, joins host DrDoes ApoB Trump Non-HDL Measurements?
https://reachmd.com/programs/lipid-luminations/does-apob-trump-non-hdl-measurements/3181/Consensus is building around apolipoprotein B (apoB) as the preferred tool for gauging the effectiveness of LDL-lowering therapies. Is it accurate, reproducible and cost-effective? Host Dr. Larry Kaskel welcomes Dr. Allan Sniderman, professor of cardiology at the McGill University Health Centre in MThe Cost-Benefit Calculus of CT Angiograms
https://reachmd.com/programs/heart-matters/the-cost-benefit-calculus-of-ct-angiograms/4047/Measuring precise risks in medicine can be a tricky proposition. Factoring risk into cost-benefit analyses can make the situation even less clear. In many ways, this is where we stand with coronary computed tomography angiograms: a scan can be immediately helpful in emergent circumstances, but at ot